Diffuse large B-cell lymphoma is the most common type of lymphoma. It makes up approximately 25% of all non-Hodgkin’s lymphomas, which are cancers that lack defining cells called Hodgkin cells ...

HYDERABAD: The first FDA-approved therapy for first-line treatment of Diffuse Large B-cell lymphoma (DLBCL) has been brought to India. A new antibody-drug conjugate (ADC) Polatuzumab combined with ...

The median progression-free survival in each arm was 13.8 months versus 3.6 months, with respective 18-month progression-free survival rates of 46.5% versus 23.0%. The objective response rates in the ...